UPDATE: Keryx (KERX) Says KRX-0401 + Xeloda Did Not Meet Primary Endpoint in Phase 3
Tweet Send to a Friend
Get Alerts KERX Hot Sheet
Up)
Trade KERX Now!
(Updated - April 2, 2012 7:06 AM EDT)
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reported today that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
This Phase 3 trial was conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. 468 patients at sixty-five U.S. sites participated in this study.
KRX-0401 (perifosine) is in-licensed by Keryx from AeternaZentaris Inc. (Nasdaq: AEZS) in the United States, Canada and Mexico.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) reported today that the Phase 3 "X-PECT" (Xeloda + Perifosine Evaluation in Colorectal cancer Treatment) clinical trial evaluating perifosine (KRX-0401) + capecitabine (Xeloda) in patients with refractory advanced colorectal cancer did not meet the primary endpoint of improving overall survival versus capecitabine + placebo.
This Phase 3 trial was conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA. 468 patients at sixty-five U.S. sites participated in this study.
KRX-0401 (perifosine) is in-licensed by Keryx from AeternaZentaris Inc. (Nasdaq: AEZS) in the United States, Canada and Mexico.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Boston Scientific (BSX) Reports Positive Results from NG PROMUS, EVOLVE
- Intel (INTC) Processor Might Replace ARM (ARMH) in Galaxy 10.1
- J.P. Morgan (JPM) CEO Dimon Might Have Enough Votes to Stay Chairman - NY Times
Create E-mail Alert Related Categories
Corporate News, FDA, Trading Halts
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
